Ethris, AstraZeneca and MedImmune to Collaborate on Developing Respiratory Disease Therapies
Asthma, COPD, Idiopathic Pulmonary Fibrosis, News
Ethris has entered into a five-year research partnership with AstraZeneca and its subsidiary MedImmune to develop mRNA-based therapies for lung diseases. The partnership will use Ethris’ proprietary SNIM®RNA technology. The nucleic acid ... Read more